WVXU: Certain cancer treatments & COVID-19 could lead to death

Recent research shows combinations of treatments given at certain times could mean worse outcomes

A University of Cincinnati study found that cancer patients undergoing a combination of chemotherapy and immunotherapy one to three months prior to a COVID-19 diagnosis have a greater risk of death than patients who haven't undergone cancer treatment in the past year.

These findings were presented Saturday at the European Society for Medical Oncology Virtual Congress 2020.

Lead author Trisha Wise-Draper, MD, PhD, associate professor of medicine in the Division of Hematology and Oncology at UC, UC Health oncologist and member of the UC Cancer Center, and her team analyzed 3,600 patients from 122 institutions across the country for this study.

"Any way you slice it, this is not good news for patients who are fighting cancer," she says. "Targeted therapies, especially those causing immune cell depletion, used one to three months before (the diagnosis of COVID-19) are associated with very high mortality, up to 50%."

Read the full WVXU report.

Read the UC News release.

Photo of chemotherapy courtesy of the National Cancer Institute.

Next Lives Here

The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.

Related Stories

2

WLWT: UC students experience realities of life in prison as part...

May 1, 2024

One day a week, eight UC students travel to the institution as part of the Inside-Out Prison Exchange Program, where they and eight incarcerated individuals discuss criminal justice topics such as sentencing, parole, life after prison and recidivism in a classroom setting. The program is part of a class taught by J.Z. Bennett, an assistant professor of criminal justice.

Debug Query for this